Adenocarcinoma Clinical Trial
Official title:
A Randomized, Double-blind, Multicenter Phase II Trial With Gemcitabine Plus Sorafenib Versus Gemcitabine Plus Placebo in Patients With Chemo-naive Advanced or Metastatic Adenocarcinoma of the Biliary Tract
This trial will be conducted to evaluate the efficacy, safety and tolerability of a
combination of gemcitabine plus sorafenib in comparison of gemcitabine plus placebo as a
first-line palliative therapy in chemo-naive advanced or metastatic CCC. There is strong
scientific rationale for exploring the role of sorafenib in combination with gemcitabine in
advanced CCC.
Sorafenib is a novel signal transduction inhibitor that prevents tumor cell proliferation
and angiogenesis through blockade of the Raf/MEK/ERK pathway at the level of Raf kinase and
the receptor tyrosine kinases VEGF-R2, R3 and PDGFR-β.
Mutations in these signaling pathways display by far the most common genetic alterations in
CCC and overexpression correlates to poor prognosis. Furthermore, there is no evidence of a
consistent or meaningful pharmacokinetic interaction between sorafenib and gemcitabine,
suggesting that sorafenib can safely be combined with gemcitabine.
Clinical results of a combination of sorafenib and gemcitabine in a phase I study in
pancreatic cancer suggested a therapeutic effect, and the safety and efficacy results
together with the knowledge of the molecular pathology of CCC provide a rationale for a
randomized, placebo-controlled phase II trial consisting of gemcitabine plus sorafenib in
advanced CCC.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05678218 -
Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma
|
||
| Recruiting |
NCT05161572 -
Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer
|
Phase 2 | |
| Recruiting |
NCT02292641 -
Beyond TME Origins
|
N/A | |
| Withdrawn |
NCT05325164 -
Methadone for 'Adenocarcinopathic' Pain Treatment
|
Phase 3 | |
| Completed |
NCT02926768 -
Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT02125240 -
Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma
|
Phase 3 | |
| Completed |
NCT02374411 -
Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients
|
N/A | |
| Completed |
NCT02454647 -
Induction Chemotherapy, Chemoradiotherapy and Surgery in Locally Advanced Gastric Cancer Patients
|
N/A | |
| Completed |
NCT01579721 -
Prospective Randomized Study of SILS Versus CLS for Rectal Cancer
|
Phase 4 | |
| Completed |
NCT01206530 -
FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT01148082 -
School Response to Families Who Have Children With Cancer
|
N/A | |
| Completed |
NCT00548548 -
A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer
|
Phase 3 | |
| Completed |
NCT00377936 -
EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas
|
Phase 2 | |
| Completed |
NCT00129844 -
Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT00183859 -
Clinical and Pharmacokinetic Trial of Intra-Abdominal Irinotecan
|
Phase 1 | |
| Recruiting |
NCT01930864 -
Metformin Plus Irinotecan for Refractory Colorectal Cancer
|
Phase 2 | |
| Completed |
NCT02498860 -
Efficacy and Safety of Adjuvant Pemetrexed Plus Cisplatin for Adenocarcinoma of Lung
|
Phase 2 | |
| Terminated |
NCT01441128 -
-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT04400474 -
Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study
|
Phase 2 | |
| Recruiting |
NCT02133196 -
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
|
Phase 2 |